 |
 |
||
 |
|||
| click on the title to jump to the abstract | ||
| hyaluronate | Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Riedl CR, Engelhardt PF, Daha KL, et al. Int Urogynecol J Pelvic Floor Dysfunct 2007 Dec 21 [Epub ahead of print] • this study evaluated the efficacy of intravesical hyaluronan therapy in 126 patients with IC/PBS and mean disease duration of 6.1 years; to be eligible for hyaluronan treatment, a positive modified potassium test was requested as a sign of a urine-tissue barrier disorder • patients were treated with weekly instillations of a 50 ml phosphate-buffered saline solution containing 40 mg sodium hyaluronate • data were obtained by a visual analogue scale (VAS) questionnaire rating from 0 to 10 that asked for global bladder symptoms before and after therapy; additional questions evaluated the therapeutic impact on quality of life • 85% of the patients reported symptom improvement (2 or more VAS units); the mean initial VAS score of 8.5 decreased to 3.5 after therapy (p<0.0001); 55% remained with no or minimal bladder symptoms after therapy (VAS 0-2); 84% reported significant improvement of their quality of life • intravesical therapy had to be initiated again with good success in 43 patients (34.5%) as symptoms recurred after discontinuation of treatment, while the rest stayed free of symptoms for up to 5 years • in general, hyaluronan therapy was well tolerated and, with the exception of mild irritative symptoms, no adverse reactions were reported for a total of 1,521 instillations • the authors conclude that timely hyaluronan instillation therapy may lead to complete symptom remission or even cure in part of the IC/PBS patients, while some responders need continuous intravesical therapy • the present results suggest that selection of patients for hyaluronan therapy by potassium testing improves the outcome of intravesical therapy with a response rate of >80% |
|
| management review | Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. |
|
| nerve stimulation | A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. |
|
| surgery | Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. |
|
| IC/PBS in OAB patients | Diagnosis of interstitial cystitis/painful bladder syndrome in patients with overactive bladder symptoms. |
|
| pain | Gain without pain in interstitial cystitis. Wyllie MG. BJU Int 2007;100:1409-10 |
|
| pelvic organ cross-sensitization | Neural mechanisms of pelvic organ cross-sensitization. Malykhina AP. Neuroscience 2007;149:660-72 • Pelvic organ cross-sensitization is considered one of the factors contributing to chronic pelvic pain of unidentified origin (including IBS and IC) • This review summarizes existing hypotheses about neural mechanisms underlying cross-sensitization in the pelvis. |
|
| intravesical treatment | Intravesical treatments for painful bladder syndrome/ interstitial cystitis. Dawson T, Jamison J. Cochrane Database Syst Rev 2007 Oct 17;(4):CD006113 • Cochrane report on intravesical treatment for PBS/IC • Evidence base for intravesical treatment is limited • Quality of trial reports mixed • BCG and oxybutynin reasonably well-tolerated; RTX showed no evidence of effect for most outcomes • Little evidence for other treatments included in this review • Randomised controlled trials and standardisation are still needed |
|
| bladder sensations | The sensory bladder (1): An update on the different sensations described in the lower urinary tract and the physiological mechanisms behind them. Wyndaele JJ, De Wachter S. Neurourol Urodyn 2007 Sep 19; [Epub ahead of print] |
|
| voiding urge | Voiding urges perceived by patients with interstitial cystitis/painful bladder syndrome. Greenberg P, Brown J, Yates T, et al. Neurourol Urodyn 2007 Oct 11; [Epub ahead of print] |
|
| autoimmune diseases | Interstitial cystitis and systemic autoimmune diseases. van de Merwe JP. Nat Clin Pract Urol 2007;4:484-91 • a review |
|
| criteria | Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC Proposal. van de Merwe JP, Nordling J, Bouchelouche P, et al. Eur Urol 2008;53:60-7 |
|
| PUF questionnaire | Validity of Pelvic Pain, Urgency, and Frequency Questionnaire in Patients with Interstitial Cystitis/Painful Bladder Syndrome. Brewer ME, White WM, Klein FA, et al. Urology 2007;70:646-9 • as determined by the correlation with the findings at cystoscopy with hydrodistension, the PUF (pain, urgency, frequency) questionnaire appears to be neither a reliable predictor of IC/PBS nor a valuable predictor of disease severity |
|
| crosstalk | Organ crosstalk modulates pelvic pain. Rudick CN, Chen MC, Mongiu AK, Klimpp DJ. Am J Physiol Regul Integr Comp Physiol 2007;293:R1191-8 |
|
| pelvic floor | Prevalence of pelvic floor dysfunction in patients with interstitial cystitis. Peter KM, Carrico DJ, Kalinowski SE, et al. Urology 2007;70:16-8 PMID: 1765199 |
|
| BCG | Did Patients With Interstitial Cystitis Who Failed to Respond to Initial Treatment With Bacillus Calmette-Guerin or Placebo in a Randomized Clinical Trial Benefit From a Second Course of Open Label Bacillus Calmette-Guerin? Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, Burks D, Kusek JW, Nyberg LM, Foster HE; Interstitial Cystitis Clinical Trials Group. J Urol 2007;178(3 Pt 1):886-90 • the authors conclude that the low response rate for bacillus Calmette-Guerin in this open label case series further argues against the routine use of bacillus Calmette-Guerin as treatment for interstitial cystitis |
|
| consensus meeting USA | A Multidisciplinary Consensus Meeting on IC/PBS: Outcome of the Consensus Meeting on Interstitial Cystitis/Painful Bladder Syndrome, February 10, 2007, Washington, DC. Chancellor MB. Rev Uro. 2007;9:81-3 |
|
| hyperbaric oxygen | Hyperbaric oxygen therapy for interstitial cystitis resistant to conventional treatments. Tanaka T, Kawashima H, Makino T, et al. Int J urol 2007;14:563-5 • case reports of 2 IC patients treated with hyperbaric oxygen therapy |
|
| urgency | The molecular basis of urgency: regional differences of vanilloid receptor expression in the human urinary bladder. Liu L, Mansfield KJ, Kristiana I, et al. Neurourol Urodyn 2007;26:433-8 |
|
| CP/CPPS | Chronic prostatitis/chronic pelvic pain syndrome and male interstitial cystitis: enigmas and opportunities. Forrest JB, Nickel JC, Moldwin RM. Urology 2007;69(4 Suppl):60-3. |
|
| treatment | Rational approaches to the treatment of patients with interstitial cystitis. |
|
| comestibles | Effect of Comestibles on Symptoms of Interstitial Cystitis. Shorter B, Lesser M, Moldwin RM, Kushner L. J Urol 2007;178:145-52 • patients with painful bladder syndrome/interstitial cystitis 90.2% indicated that the consumption of certain foods or beverages caused symptom exacerbation • there was no correlation between allergies and the effect of comestibles on symptoms • the most frequently reported and most bothersome comestibles were coffee, tea, soda, alcoholic beverages, citrus fruits and juices, artificial sweeteners and hot pepper |
|
| fibromyalgia bladder index | The Fibromyalgia Bladder Index. Brand K, Littlejohn G, Kristjanson L, et al. Clin Rheumatol 2007;26:2097-103 • the aim of this study was to determine whether the Interstitial Cystitis Symptom and Problem Index (ICSI/ICPI), is a valid, reliable, and clinically relevant instrument to assess the sensory urinary symptoms in women with fibromyalgia syndrome (FM) • factor analysis displayed two separate components of symptom and problem combinations as distinct from the original ICSI/ICPI developed for the interstitial cystitis population • the eight items of the index configured differently and formed two subscales of a newly developed Fibromyalgia Bladder Index • the two subscales of this index include the Bladder Urgency and Pain Subscale and the Bladder Frequency and Nocturia Subscale. |
|
| ketamine | Ketamine-Associated Ulcerative Cystitis: A New Clinical Entity. Shahani R, Streutker C, Dickson B, Stewart RJ. Urology 2007;69:810-2 • ketamine is an anesthetic agent that is increasingly being used as a recreational drug • the authors describe a series of 9 patients, all of whom were daily ketamine users, who presented with severe dysuria, frequency, urgency, and gross hematuria; the urine cultures were sterile in all cases • CT revealed marked thickening of the bladder wall, a small capacity, and perivesicular stranding, consistent with severe inflammation; at cystoscopy, all patients had severe ulcerative cystitis. • biopsies in 4 patients revealed epithelial denudation and inflammation with a mild eosinophilic infiltrate • cessation of ketamine use, with the addition of pentosan polysulfate, appeared to provide some symptomatic relief |
|
| pregnancy | Pregnancy and interstitial cystitis/painful bladder syndrome. Erickson DR, Propert KJ. Urol Clin North Am 2007;34:61-9 |
|
| sexual function | Interstitial cystitis and female sexual dysfunction. Ottem DP, Carr LK, Perks AE, et al. Urology 2007;69:608-10 • the authors conclude that female patients with IC have sexual dysfunction, including pain, more commonly than do controls |
|
| sexual function | Sexual Function is a Determinant of Poor Quality of Life for Women With Treatment Refractory Interstitial Cystitis. Nickel JC, Tripp D, Teal V, et al. J Urol 2007;177:1832-6 • this study identifies sexual functioning as a primary predictor of mental quality of life in women with long- standing interstitial cystitis |
|
| OAB | The overactive bladder syndrome: treating patients on an individual basis. |
|
| self-reported prevalence of IC | Prevalence of self-reported interstitial cystitis (IC) and interstitial-cystitis-like symptoms among adult women in the community. Ibrahim IA, Diokno AC, Killinger KA, et al. Int Urol Nephrol 2007;39:489-95 • the prevalence rates of self-reported IC and IC-like symptoms among controls in the community were 3.7% and 4.4%, respectively |
|
| OAB and IC/PBS | Diagnosis of interstitial cystitis/ painful bladder syndrome in patients with overactive bladder symptoms. Macdiarmid SA, Sand PK. Rev Urol 2007;9:9-16 • overactive bladder (OAB) and interstitial cystitis (IC) have similar symptoms, including urinary urgency/frequency and nocturia, making them difficult to differentiate on the basis of clinical presentation alone • the authors propose a diagnostic framework that may be useful for differentiating IC from OAB and for facilitating appropriate treatment |
|
| bacteriuria | There is a low incidence of recurrent bacteriuria in painful bladder syndrome/interstitial cystitis patients followed longitudinally. |
|
| bladder endometriosis | Update on the diagnosis and treatment of bladder endometriosis. |
|
painful bladder symptoms
|
Prevalence of painful bladder symptoms and effect on quality of life in black, hispanic and white men and women. Clemens JQ, Link CL, Eggers PW, et al. J Urol 2007;177:1390-4 • a population based cross-sectional survey of 5506 individuals was done in the Boston area for symptoms of painful bladder symptoms (PBS, based on consensus statements, research definitions and published articles) • the prevalence of PBS symptoms was 0.83-2.71% in women and 0.25-1.22% in men depending on the definition used; the presence of symptoms was associated with a significant adverse impact on quality of life • the findings indicate no racial/ethnic disparity and limited gender disparity in the prevalence of PBS symptoms |
|
| survey | Measuring the Urologic Iceberg: Design and Implementation of The Boston Area Community Health (BACH) Survey. McKinlay JB, Link CL. Eur Urol 2007;52:389-96 |
|
| Hyaluronic Acid: An Effective Alternative Treatment of Interstitial Cystitis, Recurrent Urinary Tract Infections, and Hemorrhagic Cystitis? Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Eur Urol 2007;51:1534-40; discussion 1540-1 • a literature review on treatment of interstitial cystitis, hemorrhagic cystitis, and recurrent urinary tract infections with hyaluronic acid; the authors conclude that the available clinical data regarding the effectiveness of hyaluronic acid as a potential treatment of cystitis patients are limited and that there is a need for randomized controlled trials see also: editorial comment |
||
S3 stimulation |
Bilateral s3 stimulator in patients with interstitial cystitis. Steinberg AC, Oyama IA, Whitmore KE. Urology 2007;69:441-3 • this retrospective study demonstrated that 15 patients diagnosed with interstitial cystitis with the symptoms of frequency, urgency, and pain had a significant decrease in frequency and nocturia with bilateral stimulator placement |
|
| sexual function after surgery | Female sexual function and activity following cystectomy and continent urinary tract diversion for benign indications: a clinical pilot study and review of literature. Elzevier HW, Nieuwkamer BB, Pelger RC, Lycklama A Nijeholt AA. J Sex Med 2007;4:406-16 • the authors conclude that despite extensive surgery, female sexuality may remain unchanged or even improve, following cystectomy and continent diversion for benign indication; sexual inactivity postoperatively needs more attention in respect to sexual counseling |
|
| management | Toward optimal health: Philip Hanno, M.D., M.P.H., discusses improved management of painful bladder syndrome (interstitial cystitis). Godfrey JR. J Womens Health 2007;16:3-8 |
|
| suplatast tosilate | Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation. Boucher W, Kempuraj D, Cao J, et al. J Urol 2007;177:1186-90 • the authors conlude that IPD-1151T inhibits bladder release of histamine and tumor necrosis factor-alpha through a mechanism that does not appear to involve direct mast cell inhibition |
|
| sexual function | Sexual sequelae of general medical disorders. Basson R, Schultz WW. Lancet 2007;369:409-24 |
|
| urgency | Assessing urgency in interstitial cystitis/painful bladder syndrome.
Diggs C, Meyer WA, Langenberg P, et al. Urology 2007;69:210-4 • the O'Leary-Sant Symptom Index appeared to underreport urgency • asking about urgency "with little or no warning" underestimated the prevalence and degree of urinary urgency • the authors conclude with the question that may have pathophysiological importance: "why do patients with IC/PBS have urgency ?" |
|
| urothelium | Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Birder LA, de Groat WC. Nat Clin Pract Urol 2007;4:46-54 • a review of the sensory function for the urothelium |
|
| RANTES |
RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Chen MC, Keshavan P, Gregory GD, Klumpp D. Am J Physiol Renal Physiol 2007;292:F1372-9 • this study shows that RANTES plays a key role in the pathogenesis of neurogenic cystitis and suggest that chemokines may represent novel therapeutic targets for IC patients with mast cell-associated disease (webmaster's comment: RANTES, an acronym for Regulated on Activation - Normal T Expressed and Secreted, is a cytokine that attracts a particular subset of T-lymphocytes and monocytes) |
|
| prevalence | Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project. Temml C, Wehrberger C, Riedl C, et al. Eur Urol 2007;51:803-9 • the prevalence of IC in an urban female population was 306/100,000 women • bowel disorders and psychological stress were correlated to the probability of IC • the authors conclude that the prevalence of IC symptoms is higher than previously estimated and substantially affects quality of life and sexuality |
|
| symptoms | Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. Bogart LM, Berry SH, Clemens JQ. J Urol 2007;177:450-6 • for the purpose of development of a case definition for IC in women, the authors performed a systemic literature review of symptoms of IC, PBS, vulvodynia, pelvic floor dysfunction, overactive bladder, urethral syndrome, various presentations of urinary infections, incontinence (not stress) and various presentations of endometriosis • the authors conclude that in terms of symptoms: - IC and PBS may be the same entity; recurrent urinary tract infections may be distinguished from IC and PBS via a combination of self-report and urine culture information - IC and PBS may be distinguished from OAB, vulvodynia and endometriosis, although identifying IC and PBS in women with more than 1 of these diseases may be difficult |
|
| duloxetine | The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observatinal study. van Ophoven A, Hertle L. J Urol 2007;177:552-5 • in this observational study, duloxetine was given for two months to 48 women with IC according to the NIDDK criteria • 5 patients (10.4%) responded and 17 (35.4%) dropped out due to nausea • patients who responded reported onset of improvement but not until they had reached the target dose of 2x 40 mg per day • the authors conclude that duloxetine did not result in significant improvement of symptoms in patients with IC |
|
| urinary markes and distension | Changes in urine markers and symptoms after bladder distension for interstitial cystitis. Erickson DR, Kunselman AR, Bentley CM, et al. J Urol 2007;177:556-60 |
|
NIDDK Symposium |
Frontiers in Painful Bladder Syndrome and Interstitial Cystitis. 2006 NIDDK Symposium: Summary Report, pp 1-43 |
|
| review | Interstitial cystitis pathogenesis and treatment. Mayer R. Curr Opin Infect Dis 2007;20:77-82 • a review |
|
| intravesical resiniferatoxin |
Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. |
|
| ice water | Pain during ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders. Mukerji G, Waters J, Chessell IP, et al. BMC Urol 2006;6:31 • the paper can also be downloaded from: http://www.biomedcentral.com/1471-2490/6/31 |
|
| sensory bladder | Sensory bladder disorders. Nordling J. Int J Clin Pract 2006;60(s151):38-42 |
|
| biopsy |
Discovery of morphological subgroups that correlate with severity of symptoms in interstitial cystitis: a proposed biopsy classification system. Leiby BE, Landis JR, Propert KJ, et al. J Urol 2007;177:142-8 |
|
| hydrodistension |
Bladder necrosis following hydrodistention in patients with interstitial cystitis. Zabihi N, Allee T, Maher MG, et al. J Urol 2007;177:149-52 |
|
| review articles | see also: scientific reviews, dissertations and educational articles | |
| archive | selected literature in 2007 - 2006 - 2005 - 2004 and before  |
|
| © 2006-2010 International Painful Bladder Foundation (IPBF). All rights reserved. |